[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"seasonal-allergic-rhinitis-sar\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:seasonal-allergic-rhinitis-sar":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,62,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100645137","phase-3-study-on-the-treatment-of-adolescent-patients-with-seasonal-allergic-rhinitis-100645137",false,"NCT07678931","Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Adolescent Patients With Seasonal Allergic Rhinitis Receiving Background Therapy","Inclusion Criteria:\n\n* Age range: ≥12 years to \\\u003C18 years\n* Voluntarily sign the informed consent form.\n* Seasonal allergic rhinitis has been prevalent for at least 2 years.Positive for allergens associated with seasonal allergic rhinitis.\n* Poor control of seasonal allergic rhinitis with nasal glucocorticoids or other therapeutic agents during the same pollen season in the past.\n* Weight≥40kg.\n* Symptom severity scores for the season met the enrollment criteria.\n\nExclusion Criteria:\n\n* Subjects who received anti-interleukin-4 receptor alpha(anti-IL-4Rα), anti-thymic stromal lymphopoietin(anti-TSLP), anti-immunoglobulin E(anti-IgE) monoclonal antibodies or other biologics within 10 weeks or 5 half-lives prior to screening (whichever is longer), or have a history of inadequate therapeutic response or intolerance to prior anti-IL-4Rα monoclonal antibody treatment for seasonal allergic rhinitis.\n* Subjects with known hypersensitivity to stapokibart, any anti-IL-4Rα monoclonal antibody, or any ingredients of background concomitant medications.\n* Subjects who newly initiate allergen-specific immunotherapy within 3 months before screening or intend to receive such therapy during the trial, or whose allergen exposure at home or workplace is expected to change significantly throughout the study period.\n* Subjects with poorly controlled recent asthma or concomitant severe asthma with percent predicted Forced Expiratory Volume in one second(FEV1) ≤50% at screening.\n* Subjects presenting other active nasal comorbidities at screening (chronic rhinitis, drug-induced rhinitis, chronic rhinosinusitis with or without nasal polyps, severe nasal septal deviation, etc.) that may interfere with efficacy determination.\n* Subjects with current or past history of infections of special concern (active tuberculosis, helminthic infections, severe herpes virus infections, etc.), or diagnosed with malignant tumors within 5 years before screening, excluding fully cured cervical carcinoma in situ and non-metastatic cutaneous squamous or basal cell carcinoma.\n* Subjects with severe underlying medical conditions including severe hepatic and renal impairment, autoimmune diseases, cardiovascular and cerebrovascular disorders, HIV infection, active hepatitis B\u002FC, immunosuppression, or history of solid organ\u002Fhematopoietic stem cell transplantation which, in the investigator's opinion, may pose safety risks via trial participation.\n* Have a serious underlying medical condition that, in the opinion of the investigator, may pose a risk to subject safety by participation in a clinical trial.","ALL","12 Years","18 Years",{"count":20,"type":21},136,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study aimed at evaluating the efficacy and safety of stapokibart in adolescent patients with seasonal allergic rhinitis, and observing the quality of life, Pharmakokinetics(PK), Pharmacodynamics (PD) characteristics, and immunogenicity of subjects.",[27],"Seasonal Allergic Rhinitis (SAR)","NOT_YET_RECRUITING","2026-06-25",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":21},"2026-08",{"date":36,"type":21},"2026-12",{"name":38,"class":39},"Chengdu Kangnuoxing Biopharma,Inc.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":40},"100638021","phase-2-study-of-stapokibart-injection-in-adolescent-subjects-with-seasonal-allergic-rhinitis-sar-100638021","NCT07617324","Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","A Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Pharmacokinetics of Stapokibart Injection in Adolescent Patients With SAR Under Background Therapy","Inclusion Criteria:\n\n* Voluntarily sign the Informed Consent Form.\n* Age ≥ 12 years old and \\\u003C18 years old, weight ≥ 40 kg.\n* With a diagnosis of SAR, with or without allergic conjunctivitis, and the SAR duration was ≥ 2 years.\n\nExclusion Criteria:\n\n* Not enough washing-out period for previous therapies.\n* With other poorly controlled serious diseases or chronic conditions.\n* With any conditions that are not suitable for participation in this study by investigators.",{"count":49,"type":21},15,[51],"PHASE2","This study is a multicenter, single-arm, open-label, phase II study to evaluate the safety, pharmacokinetics, and immunogenicity of Stapokibart injection in Adolescent Patients with SAR.",[27],"2026-05-24",{"date":56,"type":32},"2026-06-01",{"date":58,"type":21},"2026-06",{"date":60,"type":21},"2027-02",{"name":38,"class":39},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100639902","evaluation-of-the-efficacy-safety-and-tolerability-of-pl-14-allergy-blocker-compared-to-saline-spray-in-patients-with-seasonal-allergic-rhinitis-100639902","NCT07588672","Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis","Inclusion Criteria:\n\n1. Clinical history of seasonal AR, as reported by the subject, with symptoms for more than two years and exacerbations during the study season for the relevant seasonal allergen (e.g., tree\u002Fgrass pollen\u002Fragweed).\n2. Positive skin prick test (i.e., wheal ≥3 mm larger than the diluent control with erythema) or positive in vitro tests for specific IgE against allergen(s) relevant to the enrollment period at Baseline or within 12 months before enrollment .\n3. Age ≥ 18 years and ≤ 75 years at Screening.\n4. Active symptoms of seasonal AR with an rTNSS score ≥5 at randomization (based on the average rTNSS score during the Run-in Period and rounded to the nearest whole number).\n5. Willing and able to complete a 7-consecutive-day washout prior to the Baseline\u002FRandomization visit, during which the subject will abstain from:\n\n(1) oral or systemic H1 antihistamines, (2) topical antiallergic treatment, (3) nasal vasoconstrictors (Intermittent use of Astepro Allergy - Antihistamine (azelastine) nasal spray as rescue medication is allowed during the trial).\n\n6\\. Females must be non-pregnant and non-lactating, and at least one of the following must apply: i) not a woman of childbearing potential (WOCBP) (post-menopausal for ≥ 12 months and confirmed through testing of FSH levels ≥ 40 IU\u002FL at Screening Visit); ii) WOCBP using a contraceptive method that is highly effective (a low user-dependency method OR a user-dependent method in combination with barrier method) (plus: negative urine pregnancy test and Screening Visit, within 24 hours before the first dose of study intervention and willing to have additional pregnancy tests as required throughout the study ; iii) WOCBP abstinent from sexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention.\n\n7\\. Willing and able to attend all trial visits. 8. Able to read and understand study documents and follow instructions from the Investigator and study personnel during visits.\n\n9\\. Signed IRB\u002FEC-approved informed consent form obtained prior to any study-related procedures.\n\nExclusion Criteria:\n\n* 1\\. Presence of active, moderate or severe symptoms of non-allergic rhinitis , acute inflammation of the nose, or paranasal sinusitis at Screening or within the 7 days prior.\n\n  2\\. Positive rapid-result COVID-19 antigen test. 3. Uncontrolled asthma under treatment with any medication other than inhaled short-acting beta-2 agonists, or with known FEV1 \\\u003C 70% within the previous 6 months.\n\n  4\\. Diagnosis or symptoms of acute respiratory infection at Screening or within the previous 4 weeks.\n\n  5\\. Vaccinations: i) live vaccine(s) within 1 month prior to Screening or planned during the study; ii) killed vaccine within 1 week prior to Screening; iii) planned COVID-19 vaccine from Day -7 through Day 14.\n\n  6\\. Nasal or paranasal sinus surgery within the previous 8 weeks. 7. Long-term continuous use of inhaled or intranasal glucocorticosteroids (intermittent use is allowed).\n\n  8\\. Initiation of allergen immunotherapy within 3 months prior to Screening, or failure to have reached the maintenance phase of allergen immunotherapy at the time of enrollment, or any change in allergen immunotherapy dose or regimen within 1 month prior to Screening.\n\n  9\\. Treatment with leukotriene receptor antagonists (at Screening or within 1 week prior) or regular\u002Fchronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) at screening or within 1 week prior. Intermittent NSAID use as relief\u002Frescue medication is allowed.\n\n  10\\. Known hypersensitivity to any constituent of the study devices (test \\& control) .\n\n  11\\. Clinically significant nasal abnormalities that may interfere with proper device administration or affect nasal airflow, including but not limited to:\n  * Nasal septal deviation associated with clinically significant nasal obstruction, as determined by the investigator based on physical examination, and resulting in functional impairment (e.g., patient-reported difficulty in airflow).\n  * Nasal polyps\n  * Chronic rhinosinusitis (with or without nasal polyposis)\n  * Turbinate hypertrophy of clinical significance\n  * History of nasal surgery within the past 6 months\n  * Structural abnormalities (e.g., perforated septum, severe nasal valve collapse)\n  * Active nasal infection or acute sinusitis Subjects presenting with any of these conditions will be excluded from participation.\n\n    12\\. Any clinically relevant autoimmune, respiratory (especially with reduction of respiratory capacity) or cardiovascular disease, malignant tumors, bleeding disorders, autoimmune diseases, neurological disorders, or any other abnormality that, in the opinion of the Investigator, may pose a safety risk, confound the clinical performance or safety assessment, or interfere with study participation.\n\n    13\\. Concurrent participation in another clinical study or participation in another clinical study within 30 days prior to Screening.\n\n    14\\. A history of alcohol or drug abuse, within 2 years prior to screening, or current use of recreational drugs (particularly intranasal).\n\n    15\\. Planned travel to a region outside the designated pollen area for the Clinical Research Unit (CRU), as defined in the informed consent form, for ≥24 hours during the 7-day Run-in Period, OR for ≥2 consecutive days or a total of ≥3 days between the randomization visit and the follow-up phone call","75 Years",{"count":70,"type":21},120,[72],"NA","This study is designed to evaluate the efficacy, safety, and tolerability of PL-14 Allergy Blocker compared to saline spray in adults with Seasonal Allergic Rhinitis (SAR).\n\nPL-14 Allergy Blocker is a non-pharmacological, drug-free intranasal mucoadhesive hydrogel designed to form a mechanical barrier on the nasal mucosa and reduce contact between airborne allergens and the nasal lining.\n\nThis is a prospective, randomized, single-blind, multi-center clinical investigation in up to 120 participants at up to 8 sites in the United States. Eligible participants with a history of seasonal allergic rhinitis will be randomized in a 1:1 ratio to receive either PL-14 Allergy Blocker or Ayr® Saline Nasal Mist for up to 30 days.\n\nThe study will evaluate the effect of PL-14 Allergy Blocker on nasal allergy symptoms, quality of life, rescue medication use, and symptom-free days. Safety and local tolerability assessments will also be performed throughout this study period.",[27,75],"Allergic Rhinitis",[77,78,79,75,80,81,82,83],"PL-14","Allergy Blocker","Seasonal Allergic Rhinitis","Nasal Spray","Pollen Allergy","TNSS","RQLQ","2026-05-09",{"date":86,"type":32},"2026-05-15",{"date":88,"type":21},"2026-07-15",{"date":90,"type":21},"2027-09-30",{"name":92,"class":39},"Polyrizon Ltd.",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":16,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":40},"100609843","phase-2-a-study-to-determine-the-optimal-dose-and-frequency-of-aldp001-nasal-spray-in-adults-with-seasonal-allergic-rhinitis-under-allergen-exposure-100609843","NCT07219849","A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure","A Two-part Adaptive Double-blind Randomized Placebo-controlled Study to Assess the Appropriate Dose and the Appropriate Dosing Frequency of ALDP 001 in Adults With Seasonal Allergic Rhinitis (SAR) Assessed Using an Allergen Challenge Chamber\u002FEEC","ALDP001","Inclusion Criteria:\n\n* Diagnosis of Allergic Rhinitis (AR), as determined by the presence of seasonal rhinitis symptoms for several months per year, for more than 1 year and are not attributed to infections or nasal abnormalities\n* Positive skin prick test (SPT) response to ragweed pollen (allergen induced wheal diameter at least 3 mm larger than the negative control) in the previous 12 months\n* Healthy as determined by a responsible and experienced Investigator, based on a medical evaluation including medical history, physical examination, vital signs, ECG, and lab tests.\n\nExclusion Criteria:\n\n* Nasal abnormalities likely to affect the outcome of the study, i.e. nasal septal perforation, nasal polyps, sinusitis and other nasal malformations.\n* History of frequent nosebleeds.\n* Participants with rhinitis medicamentosa.\n* Current or chronic history of hepatic disease.\n* A QTcF (Fridericia-corrected QT interval) \\>450 ms in males or \\>470 ms in females.",true,"65 Years",{"count":104,"type":21},164,[51],"This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.",[27],[109],"ALDP001 Nasal Spray","RECRUITING","2025-10-21",{"date":113,"type":32},"2025-10-22",{"date":115,"type":32},"2025-10-17",{"date":117,"type":21},"2026-04",{"name":119,"class":39},"Alixer Nexgen Therapeutics Limited"]